Stock market announcement archive

LIFE: Lifecare receives regulatory approval to start LFC-SEN-002

November 7, 2023
Bergen, Norway, November 7th, 2023: Today, Lifecare AS (LIFE), a clinical stage medical sensor company developing the next generation Continuous Glucose Monitor (CGM), announces that The Norwegian Food Safety Authority (NFSA) has awarded all necessary approvals to start LFC-SEN-002. Reference is made to Lifecare’s list of trigger events, as presented at the semi-annual report of […]
Read more

Lifecare – New share capital registered

November 6, 2023
Reference is made to the stock exchange announcement by Lifecare AS (the "Company") published on 19 October 2023, announcing the successful completion of a private placement of 17,000,000 new shares in the Company, raising gross proceeds of NOK 42.5 million (the "Private Placement"). The share capital increase pertaining to the issuance of new shares in […]
Read more

Mandatory notification of trade

November 3, 2023
Bergen, Norway 3 November 2023: Reference is made to stock exchange notification 1 June 2022 with notification of trade of 25 000 shares by primary insider Joacim Holter. Enclosed to the stock exchange notification was a KRT 1500 form informing that the shares was planned to be transferred to Joacim Holters children. Today, Lifecare has […]
Read more

Lifecare – Valuation Report of the Sencell technology (CGM) for diabetes

November 1, 2023
Bergen, Norway, November 1st, 2023: Today, Lifecare AS (LIFE) (the “Company”), a clinical stage medical sensor company developing the next generation Continuous Glucose Monitor (CGM), publishes a new valuation report of Lifecare’s CGM-technology. The report is enclosed and available on the bottom of this text. Commissioned by Lifecare, the life science technology valuation-company Xplico has […]
Read more

LIFE: Lifecare secures funding to establish automated production and further product development.

October 20, 2023
Bergen, Norway, October 20th, 2023: Lifecare AS (LIFE) (the "Company"), aclinical stage medical sensor company developing the next generation ContinuousGlucose Monitor (CGM), has successfully completed a capital increase of NOK42,500,000 in a private placement. The equity raised ensures Lifecare's financing needs to establish automatedproduction, as well as further product development. The company's statedobjective is to […]
Read more

Lifecare – Successful completion of private placement

October 19, 2023
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN CANADA,JAPAN, AUSTRALIA OR THE UNITED STATES, OR ANY OTHER JURISDICTION IN WHICH SUCHRELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL. THIS ANNOUNCEMENT DOESNOT CONSTITUTE AN OFFER OF ANY OF THE SECURITIES DESCRIBED HEREIN. Reference is made to the announcement published on 19 October 2023 by LifecareAS […]
Read more

Lifecare – Contemplated private placement

October 19, 2023
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN CANADA,JAPAN, AUSTRALIA OR THE UNITED STATES, OR ANY OTHER JURISDICTION IN WHICH SUCHRELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL. THIS ANNOUNCEMENT DOESNOT CONSTITUTE AN OFFER OF ANY OF THE SECURITIES DESCRIBED HEREIN. Lifecare AS ("Lifecare" or the "Company") has retained Carnegie AS as bookrunnerand manager […]
Read more

LIFE: Confirmation from Norwegian Medicines Agency

October 17, 2023
Bergen, Norway, October 17th, 2023: Today, Lifecare AS (LIFE), a clinical stagemedical sensor company developing the next generation Continuous Glucose Monitor(CGM), can reveal an important announcement about regulatory confirmation fromNorwegian Medicines Agency (Statens Legemiddelverk).In the process of Lifecare's initial planning and preparations to bring SencellCGM to the veterinary market, Lifecare Veterinary has asked for regulatoryclarifications […]
Read more

Lifecare – Progress as planned towards ISO 13485 compliance

October 12, 2023
Bergen, Norway, October 12th, 2023: Today, Lifecare AS (LIFE), a clinical stagemedical sensor company developing the next generation Continuous Glucose Monitor(CGM), can disclose that Lifecare Laboratory (Mainz, Germany) is consideredready for ISO 13485 audit.ISO 13485 is a Quality Management System specific to medical devices and coversthe entire life cycle of a device, from design and […]
Read more

LIFE: Lifecare- Purchase software for automated production

October 2, 2023
Bergen, Norway, October 2nd, 2023: Lifecare AS (LIFE), a clinical stage medicalsensor company developing the next generation Continuous Glucose Monitor (CGM))has now placed the purchase order for automated production software. Reference is made to Lifecare's list of trigger events, as presented at thesemi-annual report of August 20th 2023 and later investor communication. Thelaunch of an […]
Read more